The abstract is read at the publisher; the summary is JClub's.
MTAP loss is among the most common potentially targetable driver mutations in non-small cell lung cancer (NSCLC), supporting ongoing early-phase trials.
- Why it matters: Single-arm trial results can be hard to interpret because of bias; retrospective cohort evidence can provide historical context.
- What they did: The work reviews how retrospective cohort studies can act as historical controls for early-phase studies, and how combination regimens and novel biomarkers may be used to assess response.
- The result: These approaches may improve the interpretability of early clinical findings and help raise objective response rates through better targeting and measurement.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.